These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 15992736

  • 1. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.
    Shah RR, Hondeghem LM.
    Heart Rhythm; 2005 Jul; 2(7):758-72. PubMed ID: 15992736
    [Abstract] [Full Text] [Related]

  • 2. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM.
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [Abstract] [Full Text] [Related]

  • 3. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR, Yan GX, Gallacher DJ.
    J Pharmacol Toxicol Methods; 2013 Mar; 68(2):250-259. PubMed ID: 23337247
    [Abstract] [Full Text] [Related]

  • 4. TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability).
    Hondeghem LM.
    Novartis Found Symp; 2005 Mar; 266():235-44; discussion 244-50. PubMed ID: 16050272
    [Abstract] [Full Text] [Related]

  • 5. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005 Mar; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 6. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I, Carlsson L, Duker G.
    J Pharmacol Toxicol Methods; 2011 Mar; 63(1):40-6. PubMed ID: 20451633
    [Abstract] [Full Text] [Related]

  • 7. QT and TdP. QT: an unreliable predictor of proarrhythmia.
    Hondeghem LM.
    Acta Cardiol; 2008 Feb; 63(1):1-7. PubMed ID: 18372573
    [Abstract] [Full Text] [Related]

  • 8. Drug-Induced QT Prolongation and Torsades de Pointes: An All-Exclusive Relationship or Time for an Amicable Separation?
    Hondeghem LM.
    Drug Saf; 2018 Jan; 41(1):11-17. PubMed ID: 28853038
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR, Gallacher DJ, Yan GX.
    J Pharmacol Toxicol Methods; 2016 Jan; 81():151-60. PubMed ID: 27374776
    [Abstract] [Full Text] [Related]

  • 11. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH, Wilson LD, Jeyaraj D, Fossa AA, Rosenbaum DS.
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [Abstract] [Full Text] [Related]

  • 12. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
    Aiba T, Shimizu W, Inagaki M, Noda T, Miyoshi S, Ding WG, Zankov DP, Toyoda F, Matsuura H, Horie M, Sunagawa K.
    J Am Coll Cardiol; 2005 Jan 18; 45(2):300-7. PubMed ID: 15653031
    [Abstract] [Full Text] [Related]

  • 13. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR, Hermans AN, Gallacher DJ.
    Br J Pharmacol; 2012 Jun 18; 166(4):1490-502. PubMed ID: 22300168
    [Abstract] [Full Text] [Related]

  • 14. QT prolongation is an unreliable predictor of ventricular arrhythmia.
    Hondeghem LM.
    Heart Rhythm; 2008 Aug 18; 5(8):1210-2. PubMed ID: 18675236
    [Abstract] [Full Text] [Related]

  • 15. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
    Hoffmann P, Warner B.
    J Pharmacol Toxicol Methods; 2006 Aug 18; 53(2):87-105. PubMed ID: 16289936
    [Abstract] [Full Text] [Related]

  • 16. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E, Watson T, Lip GY.
    Europace; 2007 Sep 18; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [Abstract] [Full Text] [Related]

  • 17. QTc prolongation as a surrogate for drug-induced arrhythmias: fact or fallacy?
    Hondeghem LM.
    Acta Cardiol; 2011 Dec 18; 66(6):685-9. PubMed ID: 22299377
    [Abstract] [Full Text] [Related]

  • 18. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K, Dorian P.
    Europace; 2007 Sep 18; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [Abstract] [Full Text] [Related]

  • 19. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR, Vlaminckx E, Van de Water A, Rohrbacher J, Hermans A, Gallacher DJ.
    Eur J Pharmacol; 2006 Dec 28; 553(1-3):229-39. PubMed ID: 17054943
    [Abstract] [Full Text] [Related]

  • 20. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K, Witchel HJ, McCulloch J, Sharkey J.
    Eur J Pharmacol; 2004 Oct 01; 500(1-3):129-42. PubMed ID: 15464027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.